Z
9.75
0.18 (1.88%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Zenas BioPharma, Inc. | - | - |
AIStockmoo 评分
1.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 1.25 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 24.78% |
| 机构持股比例 | 65.08% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sr One Capital Management, Lp | 30 Sep 2024 | 4,911,539 |
| Nvp Associates, Llc | 30 Sep 2024 | 1,838,482 |
| Novo Holdings A/S | 30 Sep 2024 | 1,150,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (Guggenheim, 361.54%) | 购买 |
| 中 | 35.00 (258.97%) | |
| 低 | 27.00 (Citigroup, 176.92%) | 购买 |
| 平均值 | 34.40 (252.82%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 14.20 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Dec 2024 | 30.00 (207.69%) | 购买 | 8.77 |
| Morgan Stanley | 11 Dec 2024 | 35.00 (258.97%) | 购买 | 9.16 |
| 08 Oct 2024 | 40.00 (310.26%) | 购买 | 17.69 | |
| Citigroup | 08 Oct 2024 | 27.00 (176.92%) | 购买 | 17.69 |
| Guggenheim | 08 Oct 2024 | 45.00 (361.54%) | 购买 | 17.69 |
| Jefferies | 08 Oct 2024 | 35.00 (258.97%) | 购买 | 17.69 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合